Teneligliptin improves left ventricular diastolic function and endothelial function in patients with diabetes.
Incretin hormones have been reported to have cytoprotective actions in addition to their glucose-lowering effects. We evaluated whether teneligliptin, a novel dipeptidyl peptidase-4 (DPP-4) inhibitor, affects left ventricular (LV) function in patients with type 2 diabetes mellitus (T2DM). Twenty-nine T2DM patients not receiving any incretin-based drugs were enrolled and prescribed with teneligliptin for 3 months. Compared to baseline levels, hemoglobin A1c levels decreased (7.6 ± 1.0 % to 6.9 ± 0.7 %, p < 0.01) and 1,5-anhydro-D-glucitol levels increased (9.6 ± 7.2 μg/mL to 13.5 ± 8.7 μg/mL, p < 0.01) after treatment. Clinical parameters, including body mass index and blood pressure, did not show any difference before and after treatment. Three months after treatment, there were improvements in LV systolic and diastolic function [LV ejection fraction, 62.0 ± 6.5 % to 64.5 ± 5.0 %, p = 0.01; peak early diastolic velocity/basal septal diastolic velocity (E/e') ratio, 13.3 ± 4.1 to 11.9 ± 3.3, p = 0.01]. Moreover, there was an improvement in endothelial function (reactive hyperemia peripheral arterial tonometry [RH-PAT] index; 1.58 ± 0.47 to 2.01 ± 0.72, p < 0.01). There was a significant negative correlation between changes in the E/e' ratio and RH-PAT values. Furthermore, circulating adiponectin levels increased (27.0 ± 38.5 pg/mL to 42.7 ± 33.2 pg/mL, p < 0.01) without changes in patient body weight. Teneligliptin treatment was associated with improvements in LV function and endothelial functions, and an increase in serum adiponectin levels. These results support the cardio-protective effects of teneligliptin in T2DM patients and increase in serum adiponectin levels.
Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan. t_hashikata@med.kitasato-u.ac.jp.
Takehiro
T
Hashikata
Department of Rehabilitation, Kitasato University School of Allied Health Sciences, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa, 252-0373, Japan.
Minako
M
Yamaoka-Tojo
Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan.
Ryota
R
Kakizaki
Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan.
Teruyoshi
T
Nemoto
Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan.
Kazuhiro
K
Fujiyoshi
Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan.
Sayaka
S
Namba
Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan.
Lisa
L
Kitasato
Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan.
Takuya
T
Hashimoto
Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan.
Ryo
R
Kameda
Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan.
Emi
E
Maekawa
Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan.
Takao
T
Shimohama
Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan.
Taiki
T
Tojo
Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan.
Junya
J
Ako
D052242:Adiponectin / Q000097:blood; D000368:Aged; D003847:Deoxyglucose / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D003971:Diastole; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use*; D004452:Echocardiography; D004730:Endothelium, Vascular / Q000187:drug effects*; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007564:Japan; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D011720:Pyrazoles / Q000627:therapeutic use*; D053778:Thiazolidines / Q000627:therapeutic use*; D016277:Ventricular Function, Left / Q000187:drug effects*
D052242:Adiponectin; D003847:Deoxyglucose; D054873:Dipeptidyl-Peptidase IV Inhibitors; D006442:Glycated Hemoglobin; D011720:Pyrazoles; D053778:Thiazolidines; C579035:3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine; C006584:1,5-anhydroglucitol
Adiponectin; Dipeptidyl peptidase-4 inhibitor; Endothelial function; Left ventricular function; Teneligliptin